Prognostic markers and targeted therapies for renal cell carcinoma.
Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical immunotherapy regimens yielded a therapeutic response in only 20% of patients. Advances in the understanding of molecular mechanisms of renal cell carcinoma have led to a rapidly expanding body of work exploring biomarkers for the disease and targeted therapeutics. We review current investigations into biomarkers and novel therapies for renal cell carcinoma, discuss the concept of anticancer vaccines, and propose a novel target for anticancer vaccine development.
Gimenez
S Elena
SE
James Buchanan Brady Foundation, Department of Urology, Weill Medical College of Cornell University, NY, USA.
Secasan
Ciprian
C
Raman
Jay D
JD
D014408:Biomarkers, Tumor / Q000032:analysis*; D019496:Cancer Vaccines; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D011379:Prognosis
D014408:Biomarkers, Tumor; D019496:Cancer Vaccines